Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability

European Journal of Pharmaceutical Sciences

Volumn 44, Issue 5, 2011, Pages 610-620

  Wu, Jian X ^a   Yang, Mingshi ^a   Berg, Frans Van Den ^b   Pajander, Jari ^a   Rades, Thomas ^c   Rantanen, Jukka ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Design of experiment; Image analysis; Piroxicam; Polarized light microscopy; Solid dispersion; Solvent evaporation rate

Indexed keywords

PIROXICAM; POVIDONE;

ARTICLE; CRYSTALLIZATION; DISPERSION; DRUG FORMULATION; DRUG STABILITY; EVAPORATION; HYDROGEN BOND; INFRARED SPECTROSCOPY; MICROSCOPY; MOLECULAR WEIGHT; PRIORITY JOURNAL; SOLVENT EVAPORATION RATE; THERMOGRAVIMETRY; X RAY POWDER DIFFRACTION;

ACETONE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; METHANOL; MICROSCOPY; MOLECULAR WEIGHT; PIROXICAM; POVIDONE; POWDER DIFFRACTION; PRINCIPAL COMPONENT ANALYSIS; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 82155175653     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.10.008     Document Type: Article

References (36)

1. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
2. C. Bhugra, and M.J. Pikal Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state J. Pharm. Sci. 97 2008 1329 1349
3. W.H. Buchsbaum Color TV Servicing third ed. 1975 Prentice-Hall Englewood Cliffs
4. W.L. Chiou, and S. Riegelman Pharmaceutical applications of solid dispersion systems J. Pharm. Sci. 60 1971 1281 1302
5. J. Desai, K. Alexander, and A. Riga Characterization of polymeric dispersions of dimenhydrinate in ethyl cellulose for controlled release Int. J. Pharm. 308 2006 115 123 (Pubitemid 43097242)
6. A. Forster, J. Hempenstall, and T. Rades Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers J. Pharm. Pharmacol. 53 2001 303 315 (Pubitemid 32229189)
7. A. Forster, J. Hempenstall, I. Tucker, and T. Rades The potential of small-scale fusion experiments and the Gordon-Taylor equation to predict the suitability of drug/polymer blends for melt extrusion Drug Dev. Ind. Pharm. 27 2001 549 560 (Pubitemid 32803574)
8. L. Gránásy, T. Pusztai, and T. Börzsönyi Phase field theory of nucleation and polycrystalline pattern formation J. Mater. Res. 21 2006 309 319 (Pubitemid 43292849)
9. J.E. Hilton, and M.P. Summers The effect of wetting agents on the dissolution of indomethacin solid dispersion systems Int. J. Pharm. 31 1986 157 164 (Pubitemid 16057427)
10. ICH 2009. Harmonised Tripartite Guideline: Pharmaceutical Development Q8 (R2). Fed. Regist. 71 (98).
11. S. Ingkatawornwong, N. Kaewnopparat, and V. Tantishaiyakul Studies on aging piroxicam-polyvinylpyrrolidone solid dispersions Pharmazie 56 2001 227 230 (Pubitemid 32209949)
12. S. Janssens, and G. Van den Mooter Review: physical chemistry of solid dispersions J. Pharm. Pharmacol. 61 2009 1571 1586
13. A. Karatas, N. Yüksel, and T. Baykara Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol Il Farmaco 60 2005 777 782 (Pubitemid 41317704)
14. B. Kojic-Prodic, and Z. Ruzic-Toros Structure of the anti-inflammatory drug 4-hydroxy-2-methyl-N-2-pyridyl-2H-1[lambda]6, 2-benzothiazine-3-carboxamide 1, 1-dioxide (piroxicam) Acta Crystallogr. B 38 1982 2948 2951
15. H. Konno, and L.S. Taylor Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine J. Pharm. Sci. 95 2006 2692 2705 (Pubitemid 46093176)
16. C. Leuner, and J. Dressman Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 2000 47 60 (Pubitemid 30326688)
17. T. Matsumoto, and G. Zografi Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization Pharm. Res. 16 1999 1722 1728 (Pubitemid 29530405)
18. S. Prabhu, M. Ortega, and C. Ma Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug. Piroxicam Int. J. Pharm. 301 2005 209 216 (Pubitemid 41206605)
19. G. Reck, G. Dietz, G. Laban, W. Gunther, G. Bannier, and E. Hohne X-ray studies on piroxicam modifications Pharmazie 43 1988 477 481
20. O.A. Sammour, M.A. Hammad, A.S. Zidan, and A.G. Mowafy QbD approach of rapid disintegrating tablets incorporating indomethacin solid dispersion Pharm. Dev. Technol. 16 2011 219 227
21. A.T.M. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
22. A.T.M. Serajuddin Salt formation to improve drug solubility Adv. Drug Delivery Rev. 59 2007 603 616 (Pubitemid 47285406)
23. V.J. Stella, and K.W. Nti-Addae Prodrug strategies to overcome poor water solubility Adv. Drug Deliver. Rev. 59 2007 677 694 (Pubitemid 47285410)
24. V. Tantishaiyakul, N. Kaewnopparat, and S. Ingkatawornwong Properties of solid dispersions of piroxicam in polyvinylpyrrolidone K-30 Int. J. Pharm. 143 1996 59 66 (Pubitemid 26396399)
25. V. Tantishaiyakul, N. Kaewnopparat, and S. Ingkatawornwong Properties of solid dispersions of piroxicam in polyvinylpyrrolidone Int. J. Pharm. 181 1999 143 151 (Pubitemid 29229801)
26. L.S. Taylor, and G. Zografi Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions Pharm. Res. 14 1997 1691 1698 (Pubitemid 28062912)
27. P. Thybo, J. Kristensen, and L. Hovgaard Characterization and physical stability of tolfenamic acid-PVP K30 solid dispersions Pharm. Dev. Technol. 12 2007 43 53 (Pubitemid 46902610)
28. B. Van Eerdenbrugh, and L.S. Taylor Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation Mol. Pharm. 7 2010 1328 1337
29. T. Van Nijlen, K. Brennan, G. Van den Mooter, N. Blaton, R. Kinget, and P. Augustijns Improvement of the dissolution rate of artemisin in by means of supercritical fluid technology and solid dispersions Int. J. Pharm. 254 2003 173 181 (Pubitemid 36298826)
30. R.A. Van Santen The Ostwald step rule J. Phys. Chem. 88 1984 5768 5769
31. T. Vasconcelos, B. Sarmento, and P. Costa Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs Drug Discov. Today 12 2007 1068 1075 (Pubitemid 350186132)
32. F. Vrecer, M. Vrbinc, and A. Meden Characterization of piroxicam crystal modifications Int. J. Pharm. 256 2003 3 15 (Pubitemid 36412135)
33. X. Wang, A. Michoel, and G. Van den Mooter Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole Int. J. Pharm. 303 2005 54 61 (Pubitemid 41318021)
34. S. Wold, K. Esbensen, and P. Geladi Principal component analysis Chemom. Intell. Lab. Syst. 2 1987 37 52
35. K. Wu, J. Li, W. Wang, and D.A. Winstead Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using spray drying and precipitation with compressed antisolvent J. Pharm. Sci. 98 2009 2422 2431
36. L. Yu Pharmaceutical quality by design: product and process development, understanding, and control Pharm. Res. 25 2008 781 791